ABSTRACT
Current indications for vitamin K antagonists The clinical effectiveness of vitamin K antagonists (VKAs) in the treatment of a variety of disease conditions has been established by well-designed clinical trials. VKAs are effective for the primary and secondary prevention, as well as the therapy, of venous thromboembolism, for the prevention of systemic embolism in patients with prosthetic heart valves or atrial fibrillation, and for the prevention of stroke, recurrent infarction, or death in patients with acute myocardial infarction (AMI).
